RIG-I enhances IFN-α response by promoting antiviral protein expression in patients with chronic hepatitis B.
Antivir Ther 2018 May 23. Epub 2018 May 23.
Department of Laboratory Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Background: IFN-α is widely used for the treatment of chronic hepatitis B (CHB) infection due to its high HBsAg loss. However, IFN-α treatment has a number of side effects. Thus, identification of molecular biomarkers to predict IFN-α therapeutic effect would be useful in the clinic. Read More